SuperworthBausch & Lomb EPS BLCO
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$0.48
- Latest quarter, Q2 FY26
- −$0.04
- Fiscal year 2025
- −$1.02
Bausch & Lomb's earnings per share was −$0.48 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.04.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.02 | n/a |
| FY2024 | −$0.91 | n/a |
| FY2023 | −$0.74 | −3800% |
| FY2022 | $0.02 | −96% |
| FY2021 | $0.53 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.04 | n/a | −$0.48 | |
| Q1 FY26 | −$0.20 | n/a | −$0.62 | |
| Q4 FY25 | −$0.16 | n/a | −$1.02 | |
| Q3 FY25 | −$0.08 | −900% | −$0.87 | |
| Q2 FY25 | −$0.18 | n/a | −$0.78 | |
| Q1 FY25 | −$0.60 | n/a | −$1.03 | |
| Q4 FY24 | −$0.01 | n/a | −$0.91 | |
| Q3 FY24 | $0.01 | n/a | −$1.05 | |
| Q2 FY24 | −$0.43 | n/a | −$1.30 | |
| Q1 FY24 | −$0.48 | n/a | −$0.96 | |
| Q4 FY23 | −$0.15 | n/a | −$0.74 | |
| Q3 FY23 | −$0.24 | n/a | −$0.59 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bausch & Lomb's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BLCOBausch & Lomb | −$0.48 | |
| MMSIMerit Medical Systems | $2.42 | +23% a year |
| MSAMSA Safety | $8.04 | +15% a year |
| HAEHaemonetics | $2.04 | −38% a year |
| VNTVontier | $2.41 | −8% a year |
| BMIBadger Meter | $4.28 | −8% a year |
| ICUIICU Medical | $1.18 | |
| NVSTEnvista | $0.58 | +81% a year |
| PODDInsulet | $5.35 | +64% a year |
| GMEDGlobus Medical | $3.91 | +50% a year |
| ALGNAlign Technology | $5.75 | −3% a year |
| Peer median | $3.17 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bausch & Lomb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.